Table of Contents
WILMINGTON, Del. — AstraZeneca announced that Bydureon BCise (exenatide extended-release injectable suspension 2 mg) is now available in pharmacies across the United States.
Bydureon BCise was recently approved by the U.S. Food and Drug Administration for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral antidiabetic medicines in addition to diet and exercise, to improve glycemic control.
“We’re pleased that Bydureon BCise, a new once-weekly treatment option in an easy-to-use device, is now available for adults with type 2 diabetes,” Rod Wooten, vice president of cardiovascular and metabolic diseases at AstraZeneca, said in a statement. “This new formulation helps to provide consistent glycemic control, in addition to the powerful HbA1c reductions and added benefit of weight loss, now in a simply improved device.”
Bydureon BCise is a new formulation of Bydureon (exenatide extended-release injectable suspension 2 mg) in an improved once-weekly, single-dose autoinjector device. It is designed for patient ease and convenience in a pre-filled device with a pre-attached hidden needle. AstraZeneca said Bydureon BCise is proven to reduce blood sugar levels and may have the added benefit of weight loss, although not a weight loss medicine. The medication is administered in three simple steps: mix, unlock, inject.
“Managing type 2 diabetes is complicated and requires daily attention to meal planning, exercise and medications. A once-weekly prescription option in an easy-to-use device, like BBydureon BCise, can help simplify a patient’s regimen and help them achieve diabetes control goals,” explained Virginia Valentine, executive director Medical Affairs Health-Scripts, a PromoLogics Company.
AstraZeneca said it’s committed to supporting patient access to Bydureon BCise. Eligible commercially insured patients may pay as low as $0 for Bydureon BCise every month.
